Pharmaceutical Development

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences initiates what it calls the first Phase I trial of an AI-designed oral drug formulation, approved by the UK's MHRA.

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I study of an AI-designed oral formulation, cleared by the MHRA—marking a concrete shift from AI experimentation to clin

AI-Driven Amino Acid Drugs Surface as a Promising Treatment for Eye Conditions

The rapid evolution of artificial intelligence (AI) promises to revolutionize multiple sectors, and one area seeing tangible benefits is drug development. Historically, the creation of new medicines was a time-consuming endeavor, but AI-driven amino acid research is proving to accelerate the early developmental stages and get drugs to the market faster. Researchers at the Wilmer…

How Does the COVID-19 Antiviral Medications Workflow Compare to the Traditional Antiviral Production Pipeline

As the COVID-19 pandemic continues to progress researchers and scientists are starting to learn more about the virus in order to effectively combat it. One of those lessons is how the COVID-19 virus compares to other viruses when it comes to developing treatments. Justin Honore talked to Dr. Kishor Wasan, PH.D.,FAAPS, FCAHS, FCSPS, Chief…